Searched for
CHRONIC MYELOID LEUKEMIA
These large-caps have ‘strong buy’ & ‘buy’ recos and an upside potential of up to 27%As the market seems to be in comeback mode, it helps to be aware that the best (and probably biggest) wealth creator of the last couple of ...- Stocks in news: Dr Reddy’s, Adani Green, KIMS, JSW Energy, Nestle IndiaMarkets saw a strong rebound on Friday, driven by positive global cues and easing geopolitical tensions. Nifty defended the 23,000 support ...
- These large- and mid-cap stocks can give more than 25% return in 1 year, according to analystsThere are market phases when one risk dominates. Then there are phases like this, when risks arrive from every direction and refuse to stan...
- 5 mid-cap stocks from different sectors with an upside potential of 13 to 24% in one year, according to analystsWhen mid-caps were rising, every concern on valuation was treated as unnecessary caution. Investors who advised patience were told they wer...
- These large- and mid-cap stocks may give more than 25% return in 1 year, according to analystsFor the last few earnings seasons, the message has been: “Show me growth, I have the money.” Stocks with better-than-expected earnings saw ...
- Volatility as opportunity, depends on framework of mind: 5 mid-caps from different sectors with upside potential of up to 31%The Indian stock market is no longer correcting only because of sentiment. It is now adjusting to the possibility of weaker numbers in the ...
- These large- and mid-cap stocks can give more than 20% return in 1 year, according to analystsHas a peace deal been agreed on by the US and Iran? Will the fragile ceasefire hold? No one can answer these questions with any certainty. ...
- Long-term Investing: Ecosystem with an edge called India; 12 large- mid- and small-cap stocks with upside potential of up to 34%Tactical investing should not be confused with long-term investing. In a world where geopolitical risk, commodity shocks, and uncertainty a...
- Time to take the first step to become a contrarian? 4 mid-cap stocks from different sectors with upside potential up to 21%As the risk created by the US-Iran war keeps crude oil prices elevated, the list of stocks where investors can deploy fresh money with comf...
- Merck braces for Keytruda patent loss with $6.7 billion Terns betMerck is acquiring Terns Pharma for $6.7 billion to strengthen its cancer drug pipeline, aiming to reduce reliance on its blockbuster Keytr...
- Lupin rolls out generic oncology drug in US marketDrug firm Lupin has launched a generic cancer treatment medication in the US. The company introduced Dasatinib Tablets in various strengths...
- Alembic Pharmaceuticals gets USFDA nod for generic blood cancer treatment drugAlembic Pharmaceuticals has secured final approval from the USFDA for its generic Dasatinib tablets. These tablets are used to treat certai...
- Zydus Lifesciences shares zoom 7% after USFDA nod for Dasatinib tabletsZydus Lifesciences share price: Zydus Lifesciences shares rose 7% following USFDA's final approval to market Dasatinib tablets across multi...
- Companies told to revise MRP of duty-waived medicinesIn an office memorandum dated February 17, the nodal agency for price regulation has also directed these companies to issue a revised price...
- Harvey Weinstein hospitalised after 'alarming blood test', attorney saysHarvey Weinstein was hospitalized for urgent medical care after an alarming blood test. His attorney claims the New York jail's substandard...
- #MeToo accused Hollywood producer Harvey Weinstein battling bone marrow cancer: A look at symptomsDisgraced former Hollywood producer Harvey Weinstein, who has encountered numerous legal issues, has been diagnosed with a form of bone mar...
- Aurobindo Pharma shares rise 3% after subsidiary signs license for generic version of Nilotinib CapsulesShares of Aurobindo Pharma went up by 3% after the company announced that its subsidiary Eugia Pharma has signed a voluntary license with M...
- Aurobindo Pharma arm signs pact with Medicines Patent Pool to develop anti-cancer drugIndia's Aurobindo Pharma has announced that its subsidiary Eugia Pharma Specialities has signed a voluntary sub-licensing agreement with Me...
- New study shows how blood cancer can progress, from chronic to aggressive, in someFor a small percentage, the slower-paced disease can transform into aggressive cancer.
- Sun Pharma settles Novartis lawsuit over leukemia drugSun Pharmaceutical Industries Ltd said it was allowed to launch a generic version of Novartis' leukemia drug Gleevec in the US
Load More
